Review
Oncology
Wenyu Zheng, Niu Niu, Jialong Zeng, Xianni Ke, Shi Jin
Summary: This study presents a case of a lung adenocarcinoma patient with EGFR delL747_S752 and BIM deletion polymorphism. The patient benefited from osimertinib treatment but eventually succumbed to the disease after receiving multiple therapies. The study suggests the need for more effective treatment regimens for NSCLC patients with these specific mutations.
TRANSLATIONAL CANCER RESEARCH
(2022)
Review
Oncology
Chihiro Maeda, Kanako Shinada, Shuji Murakami, Haruhiro Saito
Summary: Squamous cell carcinoma with EGFR mutations typically shows lower responsiveness to first-generation EGFR tyrosine kinase inhibitors (TKIs). However, the efficacy of osimertinib for this type of cancer is not well known. This study reports a case of a squamous cell lung cancer patient with EGFR mutations who achieved a partial response lasting more than 20 months with osimertinib treatment after prior chemoradiotherapy and durvalumab. Next-generation sequencing to confirm gene mutations and variant allele frequencies (VAF) is helpful in predicting the effectiveness of EGFR-TKIs.
Article
Oncology
Asim Joshi, Ashwin Butle, Supriya Hait, Rohit Mishra, Vaishakhi Trivedi, Rahul Thorat, Anuradha Choughule, Vanita Noronha, Kumar Prabhash, Amit Dutt
Summary: This study found that osimertinib showed significant benefit in lung cancer patients with low allele frequency of EGFR T790M mutation, and its therapeutic effect was confirmed through experiments.
TRANSLATIONAL ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Yue Zeng, Yuanqing Feng, Guihua Fu, Junlan Jiang, Xiaohan Liu, Yue Pan, Chunhong Hu, Xianling Liu, Fang Wu
Summary: The acquired resistance of EGFR-TKIs is inevitable and heterogeneous. Osimertinib is the standard second-line therapy for T790M-positive patients, but its efficacy in patients with concurrent multiple driver gene resistance is unclear. The T790M accompanying other driver gene resistance will be a new subtype, requiring new treatment options.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Jingjing Shi, Shaoyu Hao, Xiantao Liu, Yingying Li, Xin Zheng
Summary: This study found that Feiyiliu Mixture delays osimertinib resistance in EGFR-mutant cell lines and tumor-bearing mice by inhibiting PRC1/Wnt/EGFR pathway activation, reducing proliferation, and promoting apoptosis.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Maria Gabriela O. Fernandes, Catarina Sousa, Maria Jacob, Leonor Almeida, Vanessa Santos, David Araujo, Helder Novais Bastos, Adriana Magalhaes, Luis Cirnes, Conceicao Souto Moura, Henrique Queiroga, Natalia Cruz-Martins, Venceslau Hespanhol
Summary: The efficacy of osimertinib in pre-treated patients with EGFR T90M-mutated NSCLC has been demonstrated in clinical trials, but real-world data on resistance mechanisms remain limited. This study analyzed clinical outcomes and molecular results in patients with EGFR T790M-mutated NSCLC at the time of osimertinib progression, revealing diverse molecular alterations including mutations and fusions.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Michael J. Grant, Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer, Iris K. van Alderwerelt van Rosenburgh, Anna Wurtz, Andrew J. Piper-Valillo, Zofia Piotrowska, Christina Falcon, Helena A. Yu, Charu Aggarwal, Dylan Scholes, Tejas Patil, Christina Nguyen, Manali Phadke, Fang -Yong Li, Joel Neal, Mark A. Lemmon, Zenta Walther, Katerina Politi, Sarah B. Goldberg
Summary: The drug osimertinib has reduced effectiveness in treating the uncommon EGFR mutation ex19del L747_A750>P compared to the common mutation E746_A750del in non-small cell lung cancer patients. The clinical efficacy of osimertinib in treating tumors with L747_A750>P and other uncommon ex19dels is not known.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Kentaro Tanaka, Hajime Asahina, Junji Kishimoto, Yoshihiro Miyata, Takahiro Uchida, Kana Watanabe, Kosuke Hamai, Taishi Harada, Yukari Tsubata, Shunichi Sugawara, Kunihiko Kobayashi, Kenji Sugio, Satoshi Oizumi, Isamu Okamoto
Summary: The study investigated the combination of osimertinib with cytotoxic chemotherapy for EGFR-mutated NSCLC patients, finding that adding chemotherapy as a second-line treatment did not prolong survival but was generally well-tolerated.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Oncology
Longqiu Wu, Wenjuan Zhong, An Li, Zhengang Qiu, Ruilian Xie, Huaqiu Shi, Shun Lu
Summary: This case report highlights the successful treatment of a lung adenocarcinoma patient with almonertinib following osimertinib-induced ILD. The results suggest that almonertinib has a significant effect for patients with EGFR T790M mutation, with fewer side effects and better survival benefits for those with advanced lung cancer. This study provides encouraging findings and offers a novel treatment option for this patient population.
ANNALS OF TRANSLATIONAL MEDICINE
(2021)
Article
Oncology
Leiming Xia, Fan Yang, Xiao Wu, Suzhi Li, Chen Kan, Hong Zheng, Siying Wang
Summary: Our study revealed that high levels of SHP2 expression are associated with poor outcomes in LUAD patients, and SHP2 expression is enriched in Osimertinib-resistant LUAD cells. SHP2 inhibition enhances the anti-cancer effect of Osimertinib in EGFR T790M mutant LUAD by blocking the CXCL8-CXCR1/2 loop-mediated stemness.
CANCER CELL INTERNATIONAL
(2021)
Article
Oncology
Dong-Wan Kim, Sang-We Kim, D. Ross Camidge, Catherine A. Shu, Kristen A. Marrone, Xiuning Le, Collin M. Blakely, Keunchil Park, Gee-Chen Chang, Sandip Pravin Patel, Gozde Kar, Zachary A. Cooper, Ramin Samadani, Michael Pluta, Rakesh Kumar, Suresh Ramalingam
Summary: This study evaluated the combination of the anti-CD73 antibody oleclumab with the third-generation EGFR TKI osimertinib in previously treated patients with advanced EGFR-mutated NSCLC. The treatment showed moderate activity and acceptable tolerability in this patient population.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Xuanzong Li, Dai Zhang, Butuo Li, Bing Zou, Shijiang Wang, Bingjie Fan, Wanlong Li, Jinming Yu, Linlin Wang
Summary: In EGFR T790M-positive NSCLC patients, BIM-del deletion is associated with poorer clinical responses and outcomes, serving as a potential negative predictive and prognostic biomarker in osimertinib treatment.
Article
Oncology
Hye Sook Kim, Kun Young Lim, Soo-Hyun Lee, Hyae Young Kim, Youngjoo Lee, Ji-Youn Han
Summary: This study analyzed treatment failure patterns and subsequent treatment strategies in NSCLC patients treated with osimertinib. The results showed that disease progression during osimertinib treatment commonly occurred in the thorax and pre-existing metastatic sites. Thoracic metastasis was more frequent than bone or brain metastasis. These findings support the intracranial efficacy of osimertinib and can guide treatment strategies for NSCLC patients with EGFR mutations and brain metastasis.
Article
Oncology
Reheman Yiming, Yasuto Takeuchi, Tatsunori Nishimura, Mengjiao Li, Yuming Wang, Makiko Meguro-Horike, Takashi Kohno, Shin-ichi Horike, Asuka Nakata, Noriko Gotoh
Summary: EGFR-TKIs have shown efficacy in NSCLC patients with EGFR mutations, but acquired resistance remains a challenge. Increased expression of MSI2 is identified as a novel mechanism for EGFR-TKI resistance, with implications for cancer stem-like properties. Targeting the MSI2-Nanog axis in combination with EGFR-TKIs may help prevent acquired resistance.
Article
Oncology
Blake Buzard, Lindsey Douglass, Beth Gustafson, Jennifer Buckley, Marc Roth, Lara Kujtan, Dhruv Bansal
Summary: This case report highlights the benefit of using multi-gene sequencing assays to identify potential therapeutic options in patients with refractory disease. It also presents a case of sustained response to osimertinib in a colorectal cancer patient.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2023)
Letter
Oncology
Xuanzong Li, Linlin Wang, Jinming Yu
Letter
Oncology
Xuanzong Li, Ruozheng Wang, Linlin Wang
Article
Oncology
Xuanzong Li, Dai Zhang, Butuo Li, Bing Zou, Shijiang Wang, Bingjie Fan, Wanlong Li, Jinming Yu, Linlin Wang
Summary: In EGFR T790M-positive NSCLC patients, BIM-del deletion is associated with poorer clinical responses and outcomes, serving as a potential negative predictive and prognostic biomarker in osimertinib treatment.
Letter
Medicine, Research & Experimental
Xuanzong Li, Bing Zou, Shijiang Wang, Linlin Wang, Jinming Yu
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Letter
Oncology
Xuanzong Li, Jujie Sun, Linlin Wang
CLINICAL LUNG CANCER
(2021)